Molecular Modeling Evaluation of the Binding Abilities of Ritonavir and Lopinavir to Wuhan Pneumonia Coronavirus Proteases

@article{Lin2020MolecularME,
  title={Molecular Modeling Evaluation of the Binding Abilities of Ritonavir and Lopinavir to Wuhan Pneumonia Coronavirus Proteases},
  author={Shen Lin and Runnan Shen and Xushun Guo},
  journal={bioRxiv},
  year={2020}
}
An anti-HIV drug named Kaletra, composed of two protease inhibitors, ritonavir and lopinavir, might have therapeutic effect on coronavirus diseases like Wuhan pneumonia. In this study, we built the structure models of two Wuhan pneumonia coronavirus proteases, coronavirus endopeptidase C30 and papain like viral protease, by homology modeling, followed by docking ritonavir and lopinavir to the protease models, respectively. In all the simulations, the binding between ritonavir and coronavirus… Expand
Potential Drugs for Treating COVID-19 Infection
TLDR
This review article summarizes and reiterates drugs that are potentially efficient against COVID-19 and examines both pharmaceutical efficacy and safety for CO VID-19 treatment in several countries. Expand
Computational Design of Peptides to Block Binding of the SARS-CoV-2 Spike Protein to Human ACE2
TLDR
A series of peptides that can strongly bind to SARS-CoV-2 RBD are designed in computational experiments, which support the high reasonability of the designed binders, which not only recapitulated the critical native binding interactions but also introduced new favorable interactions to enhance binding. Expand
Multitarget in silico studies of Ocimum menthiifolium, family Lamiaceae against SARS-CoV-2 supported by molecular dynamics simulation
TLDR
Light is shed on the structure-based design of natural flavonoids as anti-SARS-CoV-2 drugs targeting the nsp16/10 complex and the high stability of acaciin-nsp16 complex with binding energy of −110 kJ/mol is suggested. Expand
De novo design of protein peptides to block association of the SARS-CoV-2 spike protein with human ACE2
TLDR
This study demonstrates a new avenue to utilize computationally designed peptide motifs to treat the COVID-19 disease by blocking the critical spike-RBD and hACE2 interactions. Expand
What are the drugs having potential against COVID-19?
  • K. Kucukoglu, Nagihan Faydalı, D. Bul
  • Chemistry
  • Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents
  • 2020
TLDR
All treatment options available against COVID-19 pneumonia are focused on and a great effort is made to develop effective specific therapeutic drugs, vaccines, and/or treatment strategies against these diseases. Expand
The broad-spectrum antiviral recommendations for drug discovery against COVID-19
TLDR
Different antivirals, including interferons, ribavirin, lopinavir, and monoclonal antibodies, could be the potent therapeutic agents against COVID-19 and it is recommended that these proteases, inhibitors, and antibodies could be a good therapeutic option in drug discovery to control the newly emerged coronavirus. Expand
Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China
TLDR
The general pharmacological characteristics, indications, adverse reactions, general usage, and especially current status of the treatment of COVID-19 of those potentially effective drugs, including chemical drugs, traditional Chinese medicines (TCMs), and biological products in China were summarized in this review to guide reasonable medication and the development of specific drugs for the treatment in China. Expand
Utilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges
TLDR
There is an urgent need to provide a comprehensive outlook toward utilizing drug repurposing as a tool for discovery of new therapies against COVID-19 and other respiratory infections caused by coronaviruses. Expand
A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19)
TLDR
This review summarizes the epidemiological characteristics, pathogenesis, virus structure and targeting strategies of COVID-19, and focuses on the re-purposing of clinically approved drugs and Chinese herbal medicines that may be used to treat CO VID-19 and provide new ideas for the discovery of small molecular compounds with potential therapeutic effects on novel COVID -19. Expand
Potential Drugs and Remedies for the Treatment of COVID-19: a Critical Review
TLDR
To review typical and ongoing treatments for coronavirus disease including home remedies, herbal medicine, chemical drugs, plasma therapy, and also vaccinies, famous herbal medicines and common chemical drugs which are routinely to be prescribed for patients are introduced. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 25 REFERENCES
Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitors
TLDR
To understand the fine details of the molecular interactions between these proteinase inhibitors and the SARS virus via complexation, molecular dynamics simulations were carried out and showed that flap closing was clearly observed when the inhibitors bind to the active site of SARS-CoV 3CLpro. Expand
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
TLDR
The apparent favourable clinical response with lopinavir/ritonavir and ribavirin supports further randomised placebo controlled trials in patients with SARS and shows that age, hepatitis B carrier status, and lack of treatment with this antiviral combination were independent predictors of an adverse outcome. Expand
Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial
TLDR
The aim of this study is to investigate the efficacy of treatment with a combination of lopinavir/ritonavir and recombinant IFN-β1b provided with standard supportive care in patients with laboratory-confirmed MERS requiring hospital admission. Expand
A pneumonia outbreak associated with a new coronavirus of probable bat origin
TLDR
Identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China, and it is shown that this virus belongs to the species of SARSr-CoV, indicates that the virus is related to a bat coronav virus. Expand
Pharmacologic treatment of SARS: current knowledge and recommendations.
  • D. Tai
  • Medicine
  • Annals of the Academy of Medicine, Singapore
  • 2007
TLDR
Kaletra (400 mg ritonavir and 100 mg lopinavir), a protease inhibitor used in the treatment of human immunodeficiency virus infection, may be considered for early treatment of SARS patients, preferably in a randomised double-blind placebo-controlled clinical trial setting. Expand
Origin and evolution of pathogenic coronaviruses
TLDR
The viral factors that enabled the emergence of diseases such as severe acute respiratory syndrome and Middle East respiratory syndrome are explored and the diversity and potential of bat-borne coronaviruses are highlighted. Expand
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
TLDR
Characteristics of patients who died were in line with the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia, and further investigation is needed to explore the applicability of the Mu LBSTA scores in predicting the risk of mortality in 2019-nCoV infection. Expand
Antiviral Treatment Guidelines for Middle East Respiratory Syndrome
TLDR
These guidelines focus on antiviral drugs to achieve effective treatment of MERS-CoV infections. Expand
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
TLDR
The epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of patients with laboratory-confirmed 2019-nCoV infection in Wuhan, China, were reported. Expand
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
TLDR
The epidemiological and clinical characteristics of novel coronavirus (2019-nCoV)-infected pneumonia in Wuhan, China, and hospital-associated transmission as the presumed mechanism of infection for affected health professionals and hospitalized patients are described. Expand
...
1
2
3
...